{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:05:11Z","timestamp":1758845111854,"version":"3.44.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.jaci.2004.11.029","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T10:15:04Z","timestamp":1107857704000},"page":"S361-S373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Telithromycin new product overview"],"prefix":"10.1016","volume":"115","author":[{"suffix":"Jr.","given":"Thomas M.","family":"File","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2004.11.029_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.1995.03520270048030","article-title":"Trends in antimicrobial drug prescribing among office-based physicians in the United States","volume":"273","author":"McCaig","year":"1995","journal-title":"JAMA"},{"year":"2002","series-title":"Improving treatment decisions for patients with community-acquired pneumonia","author":"Stanton","key":"10.1016\/j.jaci.2004.11.029_bib2"},{"key":"10.1016\/j.jaci.2004.11.029_bib3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0149-2918(00)88310-1","article-title":"Treatment cost of acute exacerbations of chronic bronchitis","volume":"21","author":"Niederman","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2004.11.029_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0091-6749(99)70464-1","article-title":"Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders","volume":"103","author":"Ray","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2004.11.029_bib5","series-title":"Community-acquired respiratory infections: antimicrobial management","article-title":"Overview of community-acquired respiratory tract infections","author":"File","year":"2003"},{"key":"10.1016\/j.jaci.2004.11.029_bib6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0140-6736(93)90275-L","article-title":"Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community","volume":"341","author":"MacFarlane","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2004.11.029_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0732-8893(01)00255-3","article-title":"Infectious etiologies in acute exacerbation of COPD","volume":"40","author":"Lieberman","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"suppl","key":"10.1016\/j.jaci.2004.11.029_bib8","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.113.3_Supplement.199S","article-title":"Acute exacerbations of chronic bronchitis: an international comparison","volume":"113","author":"Ball","year":"1998","journal-title":"Chest"},{"issue":"suppl","key":"10.1016\/j.jaci.2004.11.029_bib9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1067\/mhn.2002.130030","article-title":"Issues in the management of bacterial sinusitis","volume":"127","author":"Bishai","year":"2002","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaci.2004.11.029_bib10","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2004.11.029_bib11","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.45.6.1721-1729.2001","article-title":"Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995","volume":"45","author":"Doern","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0163-4453(03)00123-3","article-title":"Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01","volume":"48","author":"Doern","year":"2004","journal-title":"J Infect"},{"key":"10.1016\/j.jaci.2004.11.029_bib13","unstructured":"Nicolau DP, Jenkins SG. Resistance phenotypes and multi-drug resistance among isolates of Streptococcus pneumoniae from the US during PROTEKT US year 2 (2001-2002). Poster presented at: 41st Meeting of the Infectious Disease Society of America; October 9-12, 2003; San Diego, CA."},{"key":"10.1016\/j.jaci.2004.11.029_bib14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.40.8.1817","article-title":"Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system","volume":"40","author":"Sutcliffe","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jac\/45.2.167","article-title":"Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates","volume":"45","author":"Descheemaeker","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/AAC.35.7.1267","article-title":"Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification","volume":"35","author":"Leclercq","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1469-0691.2000.00185.x","article-title":"Ketolides\u2014telithromycin, an example of a new class of antibacterial agents","volume":"6","author":"Bryskier","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaci.2004.11.029_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM200202213460820","article-title":"Emergence of macrolide resistance during treatment of pneumococcal pneumonia","volume":"346","author":"Musher","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2004.11.029_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/318157","article-title":"Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin","volume":"31","author":"Kelley","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2004.11.029_bib20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae","volume":"35","author":"Lonks","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2004.11.029_bib21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/313976","article-title":"Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin","volume":"31","author":"Fogarty","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2004.11.029_bib22","unstructured":"Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis (ABRS). Available at:http:\/\/www.sahp.org\/revisedtreatmentguidelines.pdf. Accessed August 12, 2004."},{"key":"10.1016\/j.jaci.2004.11.029_bib23","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1086\/380488","article-title":"Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults","volume":"37","author":"Mandell","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"suppl B","key":"10.1016\/j.jaci.2004.11.029_bib24","first-page":"3B","article-title":"Canadian guidelines for the management of acute exacerbations of chronic bronchitis","volume":"10","author":"Balter","year":"2003","journal-title":"Can Respir J"},{"key":"10.1016\/j.jaci.2004.11.029_bib25","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1378\/chest.125.5.1888","article-title":"Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia","volume":"125","author":"File","year":"2004","journal-title":"Chest"},{"issue":"suppl 3","key":"10.1016\/j.jaci.2004.11.029_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1469-0691.2001.0070s3011.x","article-title":"Structure-activity relationships of ketolides vs. macrolides","volume":"7","author":"Douthwaite","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaci.2004.11.029_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00284-002-3710-0","article-title":"Telithromycin inhibition of protein synthesis and 50S ribosomal subunit formation in Streptococcus pneumoniae cells","volume":"45","author":"Champney","year":"2002","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.jaci.2004.11.029_bib28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2958.1999.01202.x","article-title":"The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA","volume":"31","author":"Hansen","year":"1999","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.jaci.2004.11.029_bib29","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1128\/JB.185.14.4276-4279.2003","article-title":"Structural insight into the antibiotic action of telithromycin against resistant mutants","volume":"185","author":"Berisio","year":"2003","journal-title":"J Bacteriol"},{"issue":"Topic T1","key":"10.1016\/j.jaci.2004.11.029_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/48.suppl_2.1","article-title":"Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site","volume":"48","author":"Douthwaite","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/40.1.85","article-title":"Ketolides lack inducibility properties of MLSB resistance phenotype","volume":"40","author":"Bonnefoy","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.44.2.414-417.2000","article-title":"In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib33","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/AAC.48.5.1882-1884.2004","article-title":"Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003","volume":"48","author":"Farrell","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2958.2000.01841.x","article-title":"Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA","volume":"36","author":"Douthwaite","year":"2000","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.jaci.2004.11.029_bib35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/dkg123","article-title":"Drugs of the 21st century: telithromycin (HMR 3647)\u2014the first ketolide","volume":"51","author":"Ackermann","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib36","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jac\/dkg153","article-title":"Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin","volume":"51","author":"Fogarty","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.idc.2004.04.010","article-title":"Macrolides and ketolides: azithromycin, clarithromycin, telithromycin","volume":"18","author":"Zuckerman","year":"2004","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jaci.2004.11.029_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000066766","article-title":"Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers","volume":"48","author":"Perret","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jaci.2004.11.029_bib39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/0036554021000026958","article-title":"Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin","volume":"34","author":"Bhargava","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jaci.2004.11.029_bib40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00003495-200161040-00003","article-title":"Review of macrolides and ketolides: focus on respiratory tract infections","volume":"61","author":"Zhanel","year":"2001","journal-title":"Drugs"},{"year":"2004","series-title":"Ketek","key":"10.1016\/j.jaci.2004.11.029_bib41"},{"key":"10.1016\/j.jaci.2004.11.029_bib42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/47.6.837","article-title":"Lung concentrations of telithromycin after oral dosing","volume":"47","author":"Khair","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib43","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1128\/AAC.41.6.1399","article-title":"Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers","volume":"41","author":"Rodvold","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib44","unstructured":"Klossek JM, Serrano E, Peynegre R, Ozoux ML, Moret G, Lescale O, et al. Penetration of telithromycin (HMR 3647), a new ketolide, into sinus tissue in patients undergoing sinusectomy. Abstract presented at: 22nd Reunion Interdisciplinaire de Chimiotherapie Ant-Infectieuse (RICAI); 2002; Paris, France. Abstract 33\/C6."},{"key":"10.1016\/j.jaci.2004.11.029_bib45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0924-8579(03)00128-6","article-title":"Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment","volume":"22","author":"Cantalloube","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jaci.2004.11.029_bib46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0091270003262952","article-title":"Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment","volume":"44","author":"Shi","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2004.11.029_bib47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1469-0691.2003.00678.x","article-title":"Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia","volume":"9","author":"Carbon","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaci.2004.11.029_bib48","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.45.1.170-175.2001","article-title":"Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses","volume":"45","author":"Namour","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/dkf085","article-title":"In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis","volume":"50","author":"Schmitz","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib50","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1128\/AAC.45.9.2427-2431.2001","article-title":"In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms","volume":"45","author":"Morosini","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1128\/AAC.43.1.90","article-title":"In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia","volume":"43","author":"Edelstein","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1128\/AAC.42.4.965","article-title":"In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine)","volume":"42","author":"Hoppe","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib53","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1128\/AAC.44.7.1846-1849.2000","article-title":"In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (telithromycin) against Chlamydia pneumoniae","volume":"44","author":"Gustafsson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.1016\/j.jaci.2004.11.029_bib54","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1086\/324526","article-title":"Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of \u03b2-lactam\u2013resistant Streptococcus pneumoniae","volume":"34","author":"File","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2004.11.029_bib55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"341","author":"Chen","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2004.11.029_bib56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jac\/49.1.173","article-title":"Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones","volume":"49","author":"McGee","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib57","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMoa012122","article-title":"Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia","volume":"346","author":"Davidson","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2004.11.029_bib58","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1592\/phco.22.5.395.33185","article-title":"Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia","volume":"22","author":"Kays","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaci.2004.11.029_bib59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/48.5.659","article-title":"Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000","volume":"48","author":"Ho","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2004.11.029_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Dunbar","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2004.11.029_bib61","unstructured":"Tellier G, Isakov T, Petermann W, Patel M, Lavin B. Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia. Abstract presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, Calif. Abstract L-373."},{"key":"10.1016\/j.jaci.2004.11.029_bib62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults","volume":"57","author":"Pullman","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jaci.2004.11.029_bib63","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"10.1016\/j.jaci.2004.11.029_bib64","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/147323000303100301","article-title":"Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis","volume":"31","author":"Zervos","year":"2003","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jaci.2004.11.029_bib65","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/rmed.2002.1382","article-title":"Telithromycin is as effective as amoxicillin\/clavulanate in acute exacerbations of chronic bronchitis","volume":"96","author":"Aubier","year":"2002","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2004.11.029_bib66","unstructured":"Fogarty C, de Wet R, Nusrat R. Five-day telithromycin is as effective as 10-day clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Available at:https:\/\/www.ersnetsecure.org\/public\/prg_congres.abstract?ww_i_presentation=11802. Accessed February 25, 2004."},{"key":"10.1016\/j.jaci.2004.11.029_bib67","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/194589240301700610","article-title":"A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis","volume":"17","author":"Buchanan","year":"2003","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.jaci.2004.11.029_bib68","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/014556130308200812","article-title":"Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin\/clavulanic acid for 10 days in acute maxillary sinusitis","volume":"82","author":"Luterman","year":"2003","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.jaci.2004.11.029_bib69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.otohns.2004.05.010","article-title":"Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis","volume":"131","author":"Ferguson","year":"2004","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaci.2004.11.029_bib70","first-page":"1","article-title":"Summary health statistics for U.S. adults: National Health Interview Survey, 2001. National Center for Health Statistics","volume":"10","author":"Lucas","year":"2004","journal-title":"Vital Health Stat"},{"key":"10.1016\/j.jaci.2004.11.029_bib71","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1164\/ajrccm.152.4.7551388","article-title":"Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush","volume":"152","author":"Monso","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2004.11.029_bib72","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMoa012561","article-title":"New strains of bacteria and exacerbations of chronic obstructive pulmonary disease","volume":"347","author":"Sethi","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2004.11.029_bib73","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jama.1995.03520360071042","article-title":"Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis","volume":"273","author":"Saint","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2004.11.029_bib74","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/srin.2000.18077","article-title":"Antibiotic therapy in acute exacerbations of chronic bronchitis","volume":"15","author":"Adams","year":"2000","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.jaci.2004.11.029_bib75","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2004.11.029_bib76","first-page":"138","article-title":"Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico","volume":"45","author":"Allegra","year":"1991","journal-title":"Ital J Chest Dis"},{"key":"10.1016\/j.jaci.2004.11.029_bib77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0091-6749(92)90169-3","article-title":"The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies","volume":"90","author":"Gwaltney","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2004.11.029_bib78","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000057670","article-title":"Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis","volume":"48","author":"Roos","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jaci.2004.11.029_bib79","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jinf.2004.03.009","article-title":"Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections","volume":"49","author":"Low","year":"2004","journal-title":"J Infect"},{"key":"10.1016\/j.jaci.2004.11.029_bib80","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","article-title":"Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group","volume":"160","author":"Heffelfinger","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2004.11.029_bib81","unstructured":"Alberta Clinical Practice Guideline working group. The management of acute exacerbations of chronic bronchitits (AECB)\/acute on chronic\/COPD. Available athttp:\/\/www.albertadoctors.org. Accessed November 18, 2004."},{"key":"10.1016\/j.jaci.2004.11.029_bib82","first-page":"11","article-title":"Primary care satisfaction among adults with physical disabilities: the role of patient-provider communication","volume":"11","author":"Kroll","year":"2003","journal-title":"Manag Care Q"},{"key":"10.1016\/j.jaci.2004.11.029_bib83","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1378\/chest.119.4.1185","article-title":"The evidence base for management of acute exacerbations of COPD: clinical practice guideline, part 1","volume":"119","author":"Snow","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2004.11.029_bib84","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1086\/379617","article-title":"Telithromycin and myasthenia gravis","volume":"37","author":"Nieman","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2004.11.029_bib85","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4065\/78.9.1113","article-title":"Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting","volume":"78","author":"Clark","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaci.2004.11.029_bib86","unstructured":"Shi J, Bhargava V, Bridson WE. Effect of grapefruit juice on the pharmacokinetics of telithromycin. Abstract presented at: American Society of Health-System Pharmacists Mid-Year Clinical Meeting; December 8-12, 2002; Atlanta, GA. Abstract A-154."},{"key":"10.1016\/j.jaci.2004.11.029_bib87","unstructured":"Shi J, Montay G, Leroy B, Bhargava V. Effects of ketoconazole and itraconazole on the pharmacokinetics of telithromycin, a new ketolide antibiotic. Abstract presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA. Abstract A-1833."},{"key":"10.1016\/j.jaci.2004.11.029_bib88","unstructured":"Montay G, Chevalier P, Guimart C, Boudraa Y, Guillaume M, Shi J, et al. A 12-hour dosing interval reduces the pharmacokinetic interaction between telithromycin and simvastatin. Abstract presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract A-1623."},{"key":"10.1016\/j.jaci.2004.11.029_bib89","unstructured":"Montay G, Chevalier P, Guimart C, Guillaume M, Shi J, Bhargava V. Effects of clarithromycin on the pharmacokinetics of simvastatin. Abstract presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract A-1624."},{"key":"10.1016\/j.jaci.2004.11.029_bib90","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/00003495-200262120-00006","article-title":"The ketolides: a critical review","volume":"62","author":"Zhanel","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2004.11.029_bib91","first-page":"33","article-title":"Antimicrobial efficacy review","volume":"7","author":"Maglio","year":"2004","journal-title":"Infect Dis"},{"volume":"46","year":"2004","key":"10.1016\/j.jaci.2004.11.029_bib92"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674904031033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674904031033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:55:34Z","timestamp":1758776134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674904031033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0091674904031033"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2004.11.029","relation":{},"ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telithromycin new product overview","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2004.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 American Academy of Allergy, Asthma and Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}